Medizone International files second patent application for AsepticSure

NewsGuard 100/100 Score

Following the recently announced success achieved during the third round of trials at its research facility at Queen's University (Kingston Ontario, Canada) Medizone International, Inc. (OTC Bulletin Board: MZEI.OB) announces that a second patent application has been filed which in combination with its previous patent application for AsepticSure™ filed in July of 2009, affords the Company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures. "This was made possible," commented Dr Michael Shannon, Medizone's Director of Medical Affairs, "through the integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative. This unprecedented success in being able to predictably achieve 6 log (99.9999%) kill rates for the causative agents of Hospital Acquired Infections (HAIs) has signaled the beginning of a new era in infectious disease control which must, as a medical imperative, be moved quickly into the hospital and chronic care domains." Shannon continued, "All samples tested during the third round of trials were either completely destroyed, that is no growth compared to the control samples, or so significantly reduced that the effect meet the 6 log definition for sterilization. The actual results of this series of tests indicate reductions in pathogens, commonly associated with HAIs, can reliably be achieved by AsepticSure™ as follows: >6.5 log for C difficile, >7 log for MRSA, 7 log for E-coli, 6.6 Log for VRE, 7 log for Pseudomonas aeruginous and > 7 log for Bacillus subtilis."  

Medizone's CEO Edwin Marshall added, "The results of our recent trials have shown that sterilization of contaminated hospital spaces with a fully portable unit is now within reach without enormous expense, which will translate into greatly reduced suffering, thousands of lives saved and a dramatic cost benefit for the health care system globally."

Medizone's research has now progressed to the full-scale mock up. By introducing the same combinations and protocols to room scale testing that produced >6 log with all HAI pathogens in the laboratory, our research team is confident the results produced should coincide with what has already been achieved in the most recent round of laboratory trials. Initial results from these scale-up trials can be expected in the near future.

SOURCE Medizone International, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Extreme heat events linked to higher odds of children's asthma hospital visits